U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07416539) titled 'Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus' on Feb. 10.
Brief Summary: This is a Phase 1a, single-country, single-centre, single-blinded, COV2 vaccine formulation randomized trial designed to investigate and compare the safety and immunogenicity of two COV2 vaccine formulations. COV2 is a nasal, investigational vaccine against COVID-19, based on a serotype 5 adenoviral vector producing modified SARS-CoV-2 spike protein.
Participants will receive one of the two COV2 formulations in two doses on Day 0 and Day 28.
This trial consists of two parts; Part 1 is a vaccination phase assessi...